AxoGen, Inc. to Participate at the American Association of Oral and Maxillofacial Surgeons 98th Annual Meeting

Increasing Awareness of Nerve Injury and Repair in Multiple Conference Presentations


The meeting will feature an AxoGen supported lecture and lab session, with additional sessions and poster presentations regarding the use of AxoGen products. AxoGen’s full portfolio of nerve assessment and nerve repair products will be featured at AAOMS Booth 868. AxoGen will also have clinical leaders in trigeminal nerve repair available at the booth during the conference. The distal trigeminal nerve is responsible for sensation in the mouth, tongue and lip, and can be injured in certain dental procedures such as third molar extraction, dental implant placement or mandible reconstruction.

“We are pleased to see the increased level of scientific discussion about nerve injury and repair at this year’s AAOMS Annual Meeting,” stated Karen Zaderej, AxoGen's President and Chief Executive Officer. “Oral and Maxillofacial injuries are a key focus for AxoGen and these clinical sessions and poster presentations, along with our continuing education initiative, reinforce AxoGen’s products as the preeminent choice for peripheral nerve repair surgery.”

The nerve related presentations for the AAOMS Meeting are as follows:

**Wednesday, September 21, 2016**

*From the Microscope to the Patient: What to Do Next In Lingual and Inferior Alveolar Nerve Injuries*

Speakers: Anthony M. Spina, Martin B. Steed, Michael Miloro, Shahrokh C. Bagheri, John R. Zuniga

**Thursday, September 22, 2016**
AxoGen Supported Lecture and Lab: **Numb Lip, Numb Chin, Numb Tongue: What to Do When**  
Speakers: Ramzey Tursun, J. Marshall Green III, Andre C. Ledoux

**Outcome of Immediate Allograft Reconstruction of Long Span Defects of the Inferior Alveolar Nerve**  
Speakers: David Salomon, Michael Miloro

**Friday, September 23, 2016**  
**Updates in Trigeminal Nerve Microsurgery**  
Speaker: Vincent B. Ziccardi

**Immediate Nerve Allograft Reconstruction with Ablation of Mandible for Benign Pathology**  
Speakers: John R. Zuniga, Fayette C. Williams, Daniel Petrisor

**Outcome of Immediate Allograft Reconstruction of Long Span Defects of the Inferior Alveolar Nerve**  
Speakers: David Salomon, Michael Miloro

**About AAOMS 2016**  
The mission of the American Association of Oral and Maxillofacial Surgeons is to promote, protect and advance oral and maxillofacial surgery to assure excellence for surgeons and their patients. For more information on the conference, please visit [www.aaoms.org](http://www.aaoms.org).

**About AxoGen**  
AxoGen (AXGN) is a global leader in innovative surgical solutions for peripheral nerve injuries. AxoGen’s portfolio of products includes Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix ("ECM") coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while minimizing soft tissue attachments. Along with these core surgical products, AxoGen also offers AxoTouch™ Two-Point Discriminator and AcroVal™ Neurosensory & Motor Testing System. These evaluation and measurement tools assist healthcare professionals in detecting changes in sensation, assessing return of sensory, grip and pinch function, evaluating effective treatment interventions, and providing feedback to patients on nerve function. The AxoGen portfolio of products is available in the United States, Canada, the United Kingdom and several European and international countries.

**Cautionary Statements Concerning Forward-Looking Statements**  
*This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "projects", "forecasts",*
"continue", "may", "should", "will" variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our growth, our 2016 guidance, product development, product potential, financial performance, sales growth, product adoption, market awareness of our products, data validation, our visibility at and sponsorship of conferences and educational events. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:
AxoGen, Inc.
Peter J. Mariani, Chief Financial Officer
386.462.6856
InvestorRelations@AxoGenInc.com

The Trout Group – Investor Relations
Brian Korb
646.378.2923
bkorb@troutgroup.com

Source: AxoGen, Inc.